AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17689407 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 19080672 — intervention group
Group type: EXPERIMENTAL
Intervention: oral metronidazole sustained release tablet 750 mg/day for 7 days
Number of subjects: 278
Study 19080672 — intervention group
Group type: EXPERIMENTAL
Intervention: oral metronidazole sustained release tablet 750 mg/day for 7 days and vaginal tinidazole 250 mg for 7 days
Number of subjects: 278
Study 19080672 — intervention group
Group type: EXPERIMENTAL
Intervention: oral tinidazole 1 g/day for 3 days (2 g for the first dose)
Number of subjects: 278
Study 19080672 — intervention group
Group type: EXPERIMENTAL
Intervention: oral ornidazole 2 x 500 mg/day for 3 days and vaginal tinidazole 250 mg for 7 days
Number of subjects: 278
Study 19080672 — intervention group
Group type: EXPERIMENTAL
Intervention: oral ornidazole 2 x 500 mg/day for 3 days
Number of subjects: 278
Study 19080672 — intervention group
Group type: EXPERIMENTAL
Intervention: oral secnidazole 2 g in a single dose and vaginal tinidazole 250 mg for 7 days
Number of subjects: 278
Study 19080672 — intervention group
Group type: EXPERIMENTAL
Intervention: oral secnidazole 2 g in a single dose
Number of subjects: 278
Study 15003546 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-based dry powder inhalers (DPIs)
Number of subjects: 14
Study 15003546 — intervention group
Group type: COMPARATOR
Intervention: Non-lactose-based dry powder inhalers (DPIs)
Number of subjects: 14
Study 15003546 — intervention group
Group type: COMPARATOR
Intervention: Metered dose inhalers (MDIs)
Number of subjects: 14
Study 15003546 — intervention group
Group type: COMPARATOR
Intervention: All inhalers tested
Number of subjects: 14
Study 11239759 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a (IFNalpha-2a)
Number of subjects: 0
Study 9231841 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (somatostatin analogue)
Number of subjects: 7
Study 9231841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7965311 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative instructions with descriptive information regarding potential sequelae and analgesic use
Number of subjects: 40
Study 7965311 — intervention group
Group type: COMPARATOR
Intervention: Basic open-ended postoperative wound care instructions
Number of subjects: 40
Study 3309236 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled amikacin (100 mg twice a day) as adjunct to intravenous ceftazidime (250 mg/kg/day) and amikacin (33 mg/kg/day)
Number of subjects: 87
Study 3309236 — intervention group
Group type: COMPARATOR
Intervention: Intravenous therapy only (ceftazidime 250 mg/kg/day and amikacin 33 mg/kg/day)
Number of subjects: 87
Study 3309236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (inhaled amikacin and intravenous therapy)
Number of subjects: 87
Study 31494275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 152
Study 31494275 — intervention group
Group type: COMPARATOR
Intervention: Tonic Spinal Cord Stimulation (SCS)
Number of subjects: 152
Study 31424158 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest models for predicting viscosities of ionic liquids
Number of subjects: 0
Study 31424158 — intervention group
Group type: EXPERIMENTAL
Intervention: MOLMAP codification system
Number of subjects: 0
Study 27296955 — intervention group
Group type: COMPARATOR
Intervention: Anorganic bovine bone graft (control)
Number of subjects: 12
Study 27296955 — intervention group
Group type: EXPERIMENTAL
Intervention: No graft (test)
Number of subjects: 12
Study 27296955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 12
Study 25234941 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (liver-ROI)
Number of subjects: 66
Study 25234941 — intervention group
Group type: COMPARATOR
Intervention: Control group (127 patients without diabetes)
Number of subjects: 66
Study 25234941 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus group (liver-ROI/heart-ROI ratio)
Number of subjects: 66
Study 24944062 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable-isotope-labeled folic acid
Number of subjects: 6
Study 24944062 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeled 5‐formyltetrahydrofolic acid (5‐FormylTHF)
Number of subjects: 6
Study 22011810 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of postpartum depressed mothers
Number of subjects: 29
Study 22011810 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls of postpartum depressed mothers
Number of subjects: 29
Study 22011810 — intervention group
Group type: COMPARATOR
Intervention: Community sample children
Number of subjects: 29
Study 22011810 — intervention group
Group type: COMPARATOR
Intervention: Girls in the community sample
Number of subjects: 29
Study 19304918 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation using a 25-mm 15-gauge monopolar cool-tip needle electrode in temperature-controlled mode
Number of subjects: 34
Study 17468789 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiGait implanted drop-foot stimulator
Number of subjects: 15
Study 16351030 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 400 mg liquid tid plus eradication treatment (500 mg clarithromycin bid and 30 mg lansoprazole bid for 10 days)
Number of subjects: 70
Study 16351030 — intervention group
Group type: COMPARATOR
Intervention: Eradication treatment only (500 mg clarithromycin bid and 30 mg lansoprazole bid for 10 days)
Number of subjects: 70
Study 12140494 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic rapid sequence intubation (RSI) with Midazolam and succinylcholine before laryngoscopy, and rocuronium after tube placement confirmation.
Number of subjects: 114
Study 12140494 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic rapid sequence intubation (RSI)
Number of subjects: 114
Study 12140494 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic rapid sequence intubation (RSI) performed on scene
Number of subjects: 114
Study 9800234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-conducted intervention (3 visits over 12 months)
Number of subjects: 222
Study 9800234 — intervention group
Group type: COMPARATOR
Intervention: General practitioner appointment (1 visit)
Number of subjects: 222
Study 7897108 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial medical treatment
Number of subjects: 13412
Study 7897108 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgical treatment
Number of subjects: 13412
Study 7897108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 13412
Study 2565266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine plus bromazepam (300 mg ranitidine and 6 mg bromazepam)
Number of subjects: 30
Study 2565266 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine plus placebo (300 mg ranitidine and placebo)
Number of subjects: 30
Study 1218169 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine
Number of subjects: 13
Study 1218169 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine with adrenaline
Number of subjects: 13
Study 1218169 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine with adrenaline
Number of subjects: 13
Study 30599756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 89
Study 30599756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 28421246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous polyspecific immunoglobulin G (IVIG) 25 g once daily for the first 3 days
Number of subjects: 100
Study 28421246 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline) equal volume once daily for the first 3 days
Number of subjects: 100
Study 26027863 — intervention group
Group type: EXPERIMENTAL
Intervention: BSSRO with extraction of the third molar
Number of subjects: 60
Study 26027863 — intervention group
Group type: COMPARATOR
Intervention: BSSRO without extraction of the third molar
Number of subjects: 60
Study 23777245 — intervention group
Group type: EXPERIMENTAL
Intervention: MobileMums program (12-week text message program)
Number of subjects: 0
Study 23777245 — intervention group
Group type: EXPERIMENTAL
Intervention: MobileMums program
Number of subjects: 0
Study 23777245 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact control group
Number of subjects: 0
Study 22230999 — intervention group
Group type: EXPERIMENTAL
Intervention: R-appliance
Number of subjects: 50
Study 22230999 — intervention group
Group type: COMPARATOR
Intervention: AIBP
Number of subjects: 50
Study 19337810 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic home exercise
Number of subjects: 102
Study 19337810 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular hyaluronate injection
Number of subjects: 102
Study 16924992 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSE, Kuraray)
Number of subjects: 30
Study 16924992 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step (ONS, BISCO Inc)
Number of subjects: 30
Study 16924992 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond SOLO Plus (OPS, Kerr)
Number of subjects: 30
Study 16924992 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop (APL, 3M ESPE)
Number of subjects: 30
Study 15117994 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐SELF Pain Control Program
Number of subjects: 174
Study 15117994 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 174
Study 11473325 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Sphincterotomy (EST)
Number of subjects: 60
Study 11473325 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Papillary Balloon Dilation (EBD)
Number of subjects: 60
Study 9466102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10 micrograms and epidural saline
Number of subjects: 58
Study 9466102 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine 20 mg and intrathecal saline
Number of subjects: 58
Study 7948823 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum carcinoembryonic antigen
Number of subjects: 123
Study 7948823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascitic fluid carcinoembryonic antigen
Number of subjects: 123
Study 7948823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascitic fluid carbohydrate antigen 19-9
Number of subjects: 123
Study 7948823 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum-ascites albumin gradient
Number of subjects: 123
Study 3332866 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 10
Study 31525441 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous PDT (blue light started immediately after ALA application for 30, 45, or 60 minutes)
Number of subjects: 23
Study 31525441 — intervention group
Group type: COMPARATOR
Intervention: Conventional PDT (blue light started 1 hour after ALA application for 1000 seconds)
Number of subjects: 23
Study 31525441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (Simultaneous and Conventional PDT)
Number of subjects: 23
Study 31125308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tide Free and Gentle® (TFG)
Number of subjects: 0
Study 31125308 — intervention group
Group type: COMPARATOR
Intervention: All Free Clear® (AFC)
Number of subjects: 0
Study 28349381 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdural drain
Number of subjects: 215
Study 28349381 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 215
Study 25785905 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cell harvesting (ACH) device
Number of subjects: 10
Study 25785905 — intervention group
Group type: COMPARATOR
Intervention: Meshed split-thickness skin graft (MSTSG)
Number of subjects: 10
Study 25785905 — intervention group
Group type: EXPERIMENTAL
Intervention: ACH
Number of subjects: 10
Study 25785905 — intervention group
Group type: COMPARATOR
Intervention: MSTSG
Number of subjects: 10
Study 23981403 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic complex (20% alcohol)
Number of subjects: 46
Study 23981403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (unmedicated vehicle)
Number of subjects: 46
Study 21419169 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza virus-like particles (VLPs) containing hemagglutinin (HA), NA, and M1 proteins
Number of subjects: 0
Study 21419169 — intervention group
Group type: EXPERIMENTAL
Intervention: NA inhibition (NAI) assay
Number of subjects: 0
Study 19606048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.15 mg/kg in 100 ml of isotonic saline)
Number of subjects: 62
Study 19606048 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (equal volume to morphine group)
Number of subjects: 62
Study 17062945 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: 1 microg/kg tramadol + 2 mg/kg propofol
Number of subjects: 80
Study 17062945 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: 1 mg/kg tramadol + 2 mg/kg propofol
Number of subjects: 80
Study 17062945 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: 50 mg flurbiprofen axetil + 2 mg/kg propofol
Number of subjects: 80
Study 17062945 — intervention group
Group type: COMPARATOR
Intervention: Group IV: 2 mg/kg propofol
Number of subjects: 80
Study 15298771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR‐1 and Lactobacillus fermentum RC‐14, daily oral intake for 2 months
Number of subjects: 11
Study 15298771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11213852 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ketoconazole 200 mg plus placebo
Number of subjects: 18
Study 11213852 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of citalopram 40 mg plus placebo
Number of subjects: 18
Study 11213852 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ketoconazole 200 mg plus single dose of citalopram 40 mg
Number of subjects: 18
Study 11213852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9761084 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (mean dosage 104+/‐37 mg/day)
Number of subjects: 70
Study 9761084 — intervention group
Group type: COMPARATOR
Intervention: d,l‐sotalol (mean dosage 242+/‐109 mg/day)
Number of subjects: 70
Study 9761084 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 70
Study 9761084 — intervention group
Group type: COMPARATOR
Intervention: d,l‐sotalol
Number of subjects: 70
Study 7920957 — intervention group
Group type: EXPERIMENTAL
Intervention: Head of bed elevation from 15 degrees to 60 degrees over 5.5 hours
Number of subjects: 120
Study 7920957 — intervention group
Group type: COMPARATOR
Intervention: Head of bed maintained at 15 degrees or less for 5.5 hours
Number of subjects: 120
Study 10288062 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive side effect management (SEM) information
Number of subjects: 60
Study 10288062 — intervention group
Group type: COMPARATOR
Intervention: Standard information provided in the setting (Control)
Number of subjects: 60
Study 31624035 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1526
Study 27876429 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylic acid
Number of subjects: 52
Study 27876429 — intervention group
Group type: COMPARATOR
Intervention: Lubricant
Number of subjects: 52
Study 25769357 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 14348
Study 25769357 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose edoxaban (60 mg)
Number of subjects: 14348
Study 25769357 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose edoxaban (30 mg)
Number of subjects: 14348
Study 25769357 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban
Number of subjects: 14348
Study 23729585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) for 6 months
Number of subjects: 251
Study 23729585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) for 6 months (first cycle)
Number of subjects: 251
Study 23729585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CR)
Number of subjects: 251
Study 22916516 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone as submucosal injection
Number of subjects: 40
Study 22916516 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 40
Study 19268383 — intervention group
Group type: EXPERIMENTAL
Intervention: Continual insulin injection
Number of subjects: 536
Study 19268383 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternation of two‐month insulin injection and four‐month secretagogue treatment
Number of subjects: 536
Study 19268383 — intervention group
Group type: COMPARATOR
Intervention: Continual secretagogue administration
Number of subjects: 536
Study 16854236 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treatment with artemether-lumefantrine (A/L)
Number of subjects: 479
Study 16854236 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised treatment with artemether-lumefantrine (A/L)
Number of subjects: 479
Study 15023204 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12700619 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐micronutrient supplementation (3.5 g/l)
Number of subjects: 977
Study 12700619 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthelminthic treatment (albendazole 600 mg and praziquantel 40 mg/kg)
Number of subjects: 977
Study 11000782 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 PCA
Number of subjects: 301
Study 11000782 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2 PCA
Number of subjects: 301
Study 11000782 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 3 PCA
Number of subjects: 301
Study 11000782 — intervention group
Group type: EXPERIMENTAL
Intervention: All PCA methods
Number of subjects: 301
Study 8842667 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blockade of the lumbar plexus with bupivacaine
Number of subjects: 20
Study 8842667 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 1468996 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative-learning-based (IL) training
Number of subjects: 0
Study 1468996 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional training
Number of subjects: 0
Study 1468996 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study 6587443 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol and progesterone
Number of subjects: 0
Study 6587443 — intervention group
Group type: COMPARATOR
Intervention: 17 beta-estradiol alone
Number of subjects: 0
Study 2829259 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg i.v.)
Number of subjects: 6
Study 2829259 — intervention group
Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 6
Study 30982443 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (300,000 IU, single muscular injection)
Number of subjects: 90
Study 30982443 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 ml, Placebo group)
Number of subjects: 90
Study 30509754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Number of subjects: 0
Study 30509754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27795561 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine and vorinostat
Number of subjects: 30
Study 27795561 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine (AZA)
Number of subjects: 30
Study 27795561 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine and vorinostat (AZA+V)
Number of subjects: 30
Study 27795561 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 30
Study 27795561 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival
Number of subjects: 30
Study 26116584 — intervention group
Group type: EXPERIMENTAL
Intervention: TEL group (n = 338)
Number of subjects: 1003
Study 26116584 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS group (n = 335)
Number of subjects: 1003
Study 26116584 — intervention group
Group type: COMPARATOR
Intervention: CONTROL group (n = 330)
Number of subjects: 1003
Study 23375496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.4 mg/kg preoperatively
Number of subjects: 40
Study 21436038 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg hydrocortisone (slow effects)
Number of subjects: 72
Study 21436038 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg hydrocortisone (rapid effects)
Number of subjects: 72
Study 21436038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20184129 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal and general anesthesia block (CSGAB)
Number of subjects: 40
Study 20184129 — intervention group
Group type: COMPARATOR
Intervention: Combined epidural and general anesthesia block (CEGAB)
Number of subjects: 40
Study 17010635 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution at 20 degrees C
Number of subjects: 60
Study 17010635 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical papaverine at 20 degrees C
Number of subjects: 60
Study 17010635 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution at 37 degrees C
Number of subjects: 60
Study 15543714 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tazarotene 0.1% gel or cream once daily for 12 weeks
Number of subjects: 468
Study 15543714 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tazarotene cream formulation
Number of subjects: 468
Study 15543714 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tazarotene gel formulation
Number of subjects: 468
Study 11758661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive treatment package
Number of subjects: 66
Study 11758661 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 66
Study 9156363 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg once daily
Number of subjects: 52
Study 9156363 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine extended‐release 5-10 mg once daily
Number of subjects: 52